Company intelligence / Profile preview

Starlight Therapeutics

Dallas, Texas, United Statesstarlightthera.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Lead candidate STAR-001 (formerly LP-184) has demonstrated blood-brain barrier permeability, favorable brain tumor bioavailability, and nanomolar potency across multiple in-vitro and in-vivo CNS cancer models. The drug received Fast Track Designation in July 2024 and is currently in Phase 1 clinical trials for high-grade glioma.

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

STAR-001

Phase 1

Indications: Glioblastoma, Brain metastases, Atypical teratoid rhabdoid tumors, Diffuse pontine glioma, High-grade gliomas

Beyond the preview

Go deeper on Starlight Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Starlight Therapeutics.

Explore the full profile